A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

NCT01707407 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacology, Clinical
Healthy

Interventions

DRUG: Pomalidomide
DRUG: Ketoconazole
DRUG: Fluvoxamine
DRUG: Carbamazepine

Sponsor

Celgene